Pegteograstim may be effective for reducing chemotherapy-induced neutropenia
the ONA take:
Pegteograstim is as effective as pegfilgrastim in reducing chemotherapy-induced neutropenia in patients with breast cancer undergoing myelosuppressive chemotherapy, a new study published online ahead of print in the journal Supportive Care in Cancer has shown.
For the phase 2/3 study, researchers sought to evaluate the efficacy and safety of pegteograstim, a new formulation of pegylated granulocyte-colony-stimulating factor (G-CSF), compared with pegfilgrastim in preventing febrile neutropenia.
In the phase 3 portion, researchers enrolled 117 patients with breast cancer who were undergoing treatment with docetaxel plus doxorubicin or docetaxel plus doxorubicin and cyclophosphamide.
Patients were randomly assigned to receive pegteofilgrastim 6.0 mg subcutaneously on day 2 of chemotherapy or pegfilgrastim 6.0 mg subcutaneously.
Results showed that the efficacy of pegteograstim was noninferior to that of pegfilgrastim in the duration of grade 4 neutropenia during cycle 1 of chemotherapy.
Furthermore, the time to absolute neutrophil count recovery was significantly shorter with pegteograstim compared with pegfilgrastim.
In regard to safety, treatment-related adverse events did not differ significantly between the two treatment arms.
Pegteograstim is as effective as pegfilgrastim in reducing chemotherapy-induced neutropenia in patients with breast cancer.
Sign Up for Free e-newsletters
- Avoiding the ED: Planned Strategies for Unplanned Urgent Cancer Care
- NP-Led Clinics Improved Phase 1 Oncology Study Operations, Outcomes
- Art as Palliative Care: Bedside Intervention Improves Pain, Anxiety, Mood in Hospitalized Cancer Patients
- Unprotected Sex After Chemotherapy
- Mindfulness Training May Improve End-of-Life Conversations in Advanced Cancer
- First Antibody-Based Treatment Regimen Approved for First-Line Treatment of Multiple Myeloma
- Increased Diabetes Risk Associated With Cancer Development
- Childhood Neuroblastoma Survivors at Risk for Psych Impairment
- Drug Classification of Trastuzumab
- Long-Term Benefits Seen With Trabectedin With PLD for Recurrent Ovarian Cancer
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|